GCP
PTGX icon

GSA Capital Partners’s Protagonist Therapeutics PTGX Stock Holding History

GSA Capital Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,884
Closed -$391K – 2003
2025
Q3 		$391K Buy
+5,884
New +$334K 0.03% 1022
2025
Q2 		– Sell
-11,963
Closed -$579K – 2075
2025
Q1 		$579K Buy
+11,963
New +$501K 0.05% 694
2024
Q4 		– Sell
-25,095
Closed -$1.13M – 1948
2024
Q3 		$1.13M Buy
25,095
+66
+0.3% +$2.67K 0.09% 393
2024
Q2 		$867K Sell
25,029
-30,330
-55% -$888K 0.06% 599
2024
Q1 		$1.6M Buy
55,359
+35,571
+180% +$968K 0.13% 199
2023
Q4 		$454K Buy
+19,788
New +$346K 0.04% 859
2023
Q1 		– Sell
-55,839
Closed -$609K – 1849
2022
Q4 		$609K Buy
55,839
+43,694
+360% +$369K 0.08% 480
2022
Q3 		$102K Buy
+12,145
New +$115K 0.01% 1361
2020
Q2 		– Sell
-30,928
Closed -$218K – 1019
2020
Q1 		$218K Sell
30,928
-36,258
-54% -$272K 0.05% 698
2019
Q4 		$474K Buy
+67,186
New +$667K 0.06% 688

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GSA Capital Partners's PTGX Position: Q4 2025 in Review

GSA Capital Partners sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 5,884 shares — an estimated $391K sold.

GSA Capital Partners first reported a position in PTGX in Q4 2019 and held it in 10 quarters. The position peaked at $1.6M in Q1 2024. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • GSA Capital Partners reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 5,884 Protagonist Therapeutics shares in Q4 2025, an estimated $391K.
  • GSA Capital Partners first reported a position in Protagonist Therapeutics in Q4 2019 and held it in 10 quarters.
  • GSA Capital Partners's Protagonist Therapeutics position peaked at $1.6M in Q1 2024.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.